MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
Sorrento Therapeutics Current Ratio 2011-2026 | SRNE
Annual Current Ratio Sorrento Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.13 | 0.894 | 0.587 | 2.91 | 0.376 | 1.18 | 4.57 | 7.73 | 5.96 | 8.99 | 9.9 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.9 | 0.376 | 4.02 |
Quarterly Current Ratio Sorrento Therapeutics
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.78 | 0.96 | 1.27 | 1.27 | 1.36 | 1.13 | 1.21 | 1.31 | 1.6 | 1.36 | 1.36 | 1.36 | 1.36 | 1.06 | 1.06 | 1.06 | 1.06 | 1.5 | 1.5 | 1.5 | 1.5 | 1.92 | 1.92 | 1.92 | 1.92 | 1.27 | 1.27 | 1.27 | 1.27 | 1.7 | 1.7 | 1.7 | 1.7 | 4.31 | 4.31 | 4.31 | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.31 | 0.78 | 1.64 |
Current Ratio of other stocks in the Biotechnology industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.02 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
28.7 | - | 1052.0 % | $ 415 M |  USA |
 |
Verastem
VSTM
|
1.3 | $ 5.04 | -4.73 % | $ 349 M | USA |
 |
Voyager Therapeutics
VYGR
|
4.49 | $ 3.96 | -4.12 % | $ 232 M | USA |
 |
VistaGen Therapeutics
VTGN
|
6.05 | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Aeterna Zentaris
AEZS
|
1.6 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
0.995 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
12.4 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
6.48 | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
6.18 | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
10.9 | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
8.96 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.59 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
0.922 | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
2.39 | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
1.34 | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
3.34 | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
2.35 | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
2.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.02 | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
10.8 | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.79 | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
3.27 | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
6.43 | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
2.02 | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.61 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
1.46 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
13.4 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
1.04 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
1.22 | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1.65 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
0.41 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
5.93 | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
1.78 | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
Wave Life Sciences Ltd.
WVE
|
5.69 | $ 6.37 | 2.66 % | $ 1.07 B |  Singapore |
 |
Xenetic Biosciences
XBIO
|
8.64 | $ 2.72 | -2.86 % | $ 4.63 M | USA |
 |
XBiotech
XBIT
|
15.4 | $ 2.27 | -1.73 % | $ 69.2 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
18.5 | $ 54.48 | -1.89 % | $ 4.24 B | Canada |
 |
Xeris Pharmaceuticals
XERS
|
1.04 | $ 5.4 | -3.05 % | $ 866 M | USA |
 |
X4 Pharmaceuticals
XFOR
|
2.79 | $ 4.04 | -6.26 % | $ 171 M | USA |
 |
Xencor
XNCR
|
3.65 | $ 11.42 | -7.23 % | $ 848 M | USA |
 |
XOMA Corporation
XOMA
|
1.62 | $ 30.17 | -1.18 % | $ 364 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2.14 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
22nd Century Group
XXII
|
3.17 | $ 2.41 | -18.03 % | $ 444 K | USA |
 |
BioDelivery Sciences International
BDSI
|
2.37 | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
1.83 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
3.05 | - | - | $ 3.74 B | USA |
 |
Zai Lab Limited
ZLAB
|
2.57 | $ 18.0 | 2.8 % | $ 19.7 B | China |
|
Enlivex Therapeutics Ltd.
ENLV
|
6.76 | $ 1.05 | -3.67 % | $ 21.5 M | Israel |
 |
Enochian Biosciences
ENOB
|
0.278 | - | - | $ 40.5 M | USA |